Sentence examples for mutations is now from inspiring English sources

Testing for KRAS mutations is now being recommended as a tailored therapeutic strategy prior to anti-EGFR treatment; however, the low sensitivity of direct sequencing frequently leads to failure of detection of KRAS mutations in clinical samples.

The identification of point mutations is now straightforward owing to advances in sequencing technology and in mutation detection.

Molecular screening for BRCA1 and BRCA2 mutations is now an established component of risk evaluation and management of familial breast cancer.

Using this adjusted fitness as initial fitness, the predicted decline from other deleterious mutations is now the component due to nonlethals, e − U nL.

Even in cases where there are obvious perinatal risk factors, an underlying genetic mutation still may be present and a thorough search for de novo mutations is now clearly warranted before the cause can be ascribed to obstetric misadventure.

Determining fitness of specific mutations is now possible using macro-evolutionary inferences and population genetics approaches [ 71- 73], which can be successfully combined with genome-wide association studies [ 74].

Targeted therapies, which are designed to disarm these mutations, are now at the forefront of care.

Interestingly, de novo mutations are now known to be rather pervasive in the brain [75, 76].

Oncogenic activating mutations are now known to occur in a number of epigenetic modifiers (i.e. IDH1/2, EZH2, DNMT3A), pinpointing epigenetic pathways that are involved in tumorigenesis.

Exemplifying this, roughly 200 variants that were previously believed to be disease-causing mutations were now revealed to be mostly harmless polymorphisms by use of the database [26, 34].

Cx mutations are now widely accepted as one of the most common human mutations causing severe sensorineural deafness.